

REMARKS

Entry of this preliminary amendment is respectfully requested.


This application is a divisional of copending application no. 09/419,761, now allowed. Claims 3-6, 8-16, 18-44, 48-52 and 56-60 have been cancelled without prejudice or disclaimer. Claims 1, 7, 17, 45-47, and 53-55 are amended to remove nonelected subject matter and to correct multiple dependencies. Claim 45 is also amended to correct a typographical error in the claims as originally filed. The compounds related to Example 5, for example, 3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid, should have properly been written as 3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid. Support for this amendment can be found in the chemical structure associated with Example 5 on page 45.

Accordingly, claims 1, 2, 7, 17, 45-47, and 53-55 are based on the corresponding claims as originally filed in the parent application and are directed to the subject matter of **Group I** which has not elected in the parent application.

In addition, the title of the invention has been amended to more accurately define the claimed invention.

Accordingly, claims 1, 2, 7, 17, 45-47, and 53-55 are pending and at issue in this application. It is respectfully submitted that the present amendment presents no new issues or new matter and that the claims are in condition for allowance, and a determination to that effect is earnestly solicited. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Date: February 8, 2002




23650

PATENT TRADEMARK OFFICE

MARKED-UP VERSION OF THE CLAIMS SHOWING AMENDMENTS MADE

1. (Amended) A compound of formula (Ia)



wherein R^1 , R^2 , R^3 , and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12} -alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, C_{1-12} -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy C_{1-12} -alkyl, amino, acylamino, C_{1-12} -alkylamino, arylamino, aralkylamino, amino C_{1-12} -alkyl, C_{1-12} -alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12} -alkoxy C_{1-12} -alkyl, aryloxy C_{1-12} -alkyl, aralkoxy C_{1-12} -alkyl, C_{1-12} -alkylthio, thio C_{1-12} -alkyl, C_{1-12} -alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, $-COR^{11}$, or $-SO_2R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6} -alkoxy or amino optionally substituted with one or more C_{1-6} -alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
or R^1 and R^2 , R^2 and R^3 and/or R^3 and R^4 may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C_{1-6} -alkyl;

ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more [halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12} -alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, C_{1-12} -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,

BOOKS

Ar represents arylene[,] or heteroarylene, [or a divalent heterocyclic group] optionally substituted with one or more C₁₋₆-alkyl or aryl;

- 11 -

R^6 represents hydrogen, hydroxy, halogen, C_{1-12} -alkoxy, C_{1-12} -alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^6 forms a bond together with R^5 ,
 R^7 represents hydrogen, C_{1-12} -alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, aryl, aralkyl, C_{1-12} -alkoxy C_{1-12} -alkyl, C_{1-12} -alkoxycarbonyl, aryloxy, carbonyl, C_{1-12} -alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
 R^8 represents hydrogen, C_{1-12} -alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
Y represents oxygen, sulphur or NR^{10} , where R^{10} represents hydrogen, C_{1-12} -alkyl, aryl, hydroxy C_{1-12} -alkyl or aralkyl groups or when Y is NR^{10} , R^8 and R^{10} may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C_{1-6} -alkyl;
n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;
or a pharmaceutically acceptable salt thereof.

7. (Amended) A compound according to [anyone of the preceding claims] claim 1 wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7} -alkyl, C_{4-7} -alkenynyl, C_{2-7} -alkenyl, C_{2-7} -alkynyl, C_{1-7} -alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy C_{1-7} -alkyl, amino, acylamino, C_{1-7} -alkylamino, arylamino, aralkylamino, amino C_{1-7} -alkyl, C_{1-7} -alkoxy C_{1-7} -alkyl, aryloxy C_{1-7} -alkyl, aralkoxy C_{1-7} -alkyl, C_{1-7} -alkylthio, thio C_{1-7} -alkyl, C_{1-7} -alkoxycarbonylamino, aryloxy, carbonylamino, aralkoxy, carbonylamino, -COR¹¹, or -SO₂R¹², wherein R¹¹ and R¹² independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C_{1-6} -alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

17. (Amended) A compound according to [anyone of the preceding claims] claim 1 wherein Ar represents arylene or heteroarylene;
 R^5 represents hydrogen, hydroxy, halogen; or R^5 forms a bond together with R^6 ,
 R^6 represents hydrogen, hydroxy, halogen; or R^6 forms a bond together with R^5 ,

R⁷ represents hydrogen, C₁₋₇-alkyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl, C₁₋₇-alkoxyC₁₋₇-alkyl, C₁₋₇-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R⁸ represents hydrogen, C₁₋₇-alkyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl;

Y represents oxygen or sulphur;

n is an integer ranging from 2 to 3 and m is 1.

45. (Amended) The compound according to claim 1 which is

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
Ethyl-3-{4-[2-(10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-
propionate,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic
acid,

[3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-methoxy-propionic
acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-methoxy-propionic
acid,]

3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,
3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-methoxy-propionic
acid,

3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,
3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-methoxy-propionic acid,
[2-Ethoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-
propionic acid,

2-Methoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-
propionic acid,

- 2-Propoxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,
- 2-Benzyloxy-3-(4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl)-propionic acid,
- 2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,
- 2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,
- 2-Benzyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propoxy]-phenyl)-propionic acid,
- 2-Ethoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,
- 2-Methoxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,
- 2-Benzyloxy-3-(4-[3-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-propyl]-phenyl)-propionic acid,
- 2-Ethoxy-3-(4-[1-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-methoxy]-phenyl)-propionic acid,
- 3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
- 3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,
- 3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,
- 3-{4-[2-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,
- 3-{4-[1-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,
- 3-{4-[3-(6,7-Dihydro-5*H*-dibenzo[*b,g*]azocin-12-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

[2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diazadibenzo[*a,d*]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[a,d]cyclohepten-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzylxy-3-{4-[2-(9-oxo-9*H*-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(9-oxo-9*H*-acridin-10-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Benzylxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Benzylxy-3-{4-[3-(9-oxo-9*H*-acridin-10-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzylxy-3-{4-[2-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propoxy]-phenyl}-propionic acid,
 2-Ethoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
 2-Propoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
 2-Methoxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
 2-Benzyloxy-3-{4-[3-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-propyl]-phenyl}-propionic acid,
 2-Ethoxy-3-{4-[1-(5-oxo-5*H*-5*H*⁴-phenothiazin-10-yl)-methoxy]-phenyl}-propionic acid,
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 3-(4-(2-(2-Chloro-5-oxo-phenothiazin-10-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 3-(4-(1-(2-Chloro-5-oxo-phenothiazin-10-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-propoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-methoxy-propionic acid,
 3-(4-(3-(2-Chloro-5-oxo-phenothiazin-10-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
 (S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 (S)-3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S)-3-(4-(1-(Betacarbolin-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-methoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-methoxy-propionic acid,
 (S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-propoxy-propionic acid,

(S)-3-(4-(3-(Betacarbolin-9-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
 3-(4-(2-(Betacarbolin-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,]
 3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
Ethyl-3-(4-(2-(dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionate,
 3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 3-(4-(1-(Dibenzo[*b,f*]azepin-5-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-propoxy-propionic acid,
 3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,
 [3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-ethoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-methoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-propoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propoxy)-phenyl-2-benzyloxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-ethoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-methoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-propoxy-propionic acid,
 3-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-propyl)-phenyl-2-benzyloxy-propionic acid,
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-ethoxy-propionic acid,
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-propoxy-propionic acid,
 1-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-methoxy)-phenyl-2-ethoxy-propionic acid,
 2-(4-Dibenzo[*d,g*]dioxazocin-12-yl)-1-ethoxy)-phenyl-2-benzyloxy-propionic acid,
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 (S) 3-(4-(2-(3-Phenyl-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S) 3-(4-(1-(3-Phenyl-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,

(S) 3-(4-(3-(3-Phenyl-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-Benzyl-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-(2-Pyridyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-(3-Furanyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-(2-thionyl)-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S) 3-(4-(2-(3-Bromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S) 3-(4-(1-(3-Bromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-(3-Bromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dibromo-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,
 (S) 3-(4-(2-(3,6 Dichloro-carbazol-9-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S) 3-(4-(1-(3,6 Dibromo-carbazol-9-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-(3,6 Dibromo-carbazol-9-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-methoxy-propionic acid,
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-propoxy-propionic acid,
 (S) 3-(4-(2-Carbazol-9-yl-ethoxy)-phenyl)-2-benzyloxy-propionic acid,
 (S) 3-(4-(1-Carbazol-9-yl-methoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-Carbazol-9-yl-propoxy)-phenyl)-2-ethoxy-propionic acid,
 (S) 3-(4-(3-Carbazol-9-yl-propyl)-phenyl)-2-ethoxy-propionic acid;]
 or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 1 which is

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,

Ethyl-3-(4-(2-(10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionate,

[2-Ethoxy-3-{4-[2-(5,11-dihydro-5H-dibenzo[*b,e*][1,4]oxazepin-5-yl)-ethoxy]-phenyl}-propionic acid,

3-{4-[2-(6,7-Dihydro-5H-dibenzo[*b,g*]azocin-12-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,]

2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

[2-Ethoxy-3-{4-[2-(11-methyl-10,10-dioxo-10,11-dihydro-10⁶-thia-5,11-diaza-dibenzo[*a,d*]cyclohepten-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(9-oxo-9H-acridin-10-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(5-oxo-5H-5⁴-phenothiazin-10-yl)-ethoxy]-phenyl}-propionic acid;] or a pharmaceutically acceptable salt thereof.

47. (Amended) A pharmaceutical composition comprising, as an active ingredient, a compound according to [anyone of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

53. (Amended) A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to [anyone of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the preceding composition claims].

54. (Amended) A method for the treatment [and/or prevention] of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to [anyone of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the preceding claims 47-52].

55. (Amended) A method for the treatment [and/or prevention] of diabetes [and/]or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to [anyone of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the preceding claims 47-52].

2020-12-29 10:07:54